Digital Diagnostics
Featured Products
Increase patient access to specialty services in a primary care setting
Expedite referrals to specialty care when disease is detected
Prevent vision loss and blindness with early detection
LumineticsCore™
Product Benefits
Reimbursement
LumineticsCore is reimbursable using CPT code 92229
30-Second Algorithm
LumineticsCore can provide a diagnosis within 30 seconds of image submission
Care Gap Closure
Closes the diabetes eye exam care gap, improving HEDIS and MIPS score and Stars ratings
Digital Diagnostics
Testimonials
Tarzana Treatment Centers
"This AI technology has improved satisfaction for both patients and the clinical team by providing clinicians with real-time data to manage diabetes more effectively. Support staff feel a sense of pride and accomplishment when explaining the technology to patients. The integration of LumineticsCore with EPIC has made our busy clinics into a convenient one stop shop. What we want in Medicine!"
MD, Medical Champion Tarzana Treatment Centers
Johns Creek Primary Care
“LumineticsCore™ really is cutting-edge technology that helps me market to patients, prevent vision loss from diabetes, and improve my quality scores”
MD, FACP Johns Creek Primary Care
Cahaba Medical Care
“An immediate point-of-care result is great to close the communications loop with the patient. The more you can get done when the patient is at the visit is better.”
MD, FAAFP, Chief Executive Officer Cahaba Medical Care
Tarzana Treatment Centers
“Patients are empowered when they see how their retina looks and what a worse outcome prognosis could be. In this case, the patient was so motivated to not lose his sight that he dropped his HbA1c within three months. We are now discussing decreasing daily insulin dosages.”
Provider Overseeing Diabetes Care
Tarzana Treatment Center
“It’s been a godsend for us.”
Director of Clinic Operations Tarzana Treatment Centers
Zufall Health
“The identification of organ damage also provides crucial feedback for the patient and medical team regarding the need for intensifying or improving overall diabetes care.”
MD Family Medicine Provider at Zufall Health Center
University Medical Center
“It’s a better and more efficient system that allows us to do more exams.”
at UMC
OSF Healthcare
“Nearly one-quarter of all patients with diabetes who received the [LumineticsCore] exam tested positive for diabetic retinopathy. The AI can see the early changes of diabetic retinopathy that we may not be able to see with our own eyes.There’s nothing as good as prevention.”
DO, VP of Community Medicine at OSF HealthCare
Digital Diagnostics Real World Evidence
Digital Diagnostics is the most researched autonomous AI diagnostic solution for diabetic eye disease
Case Study
LumineticsCore Increases Diabetic Retinopathy Detection at Johns Creek Primary Care
With the addition of LumineticsCore, adherence rates with diabetic retinal exams increased from 16.2% to 50.7% based on a year over year data comparison
Case Study
LumineticsCore Helps Address Health Equity with a High-risk Patient Population using Autonomous AI at Cahaba Medical Care
Within 90 days, LumineticsCore diagnosed one out of every three people tested with diabetic retinopathy, which would have otherwise gone undetected.
Case Study
Use of LumineticsCore Autonomous AI at Urban Health Exceeded Quality Targets and Improved Provider Efficiency
Combining eye exams for diabetes (EEDs) from eyecare providers and autonomous AI, UHP went from performing at 40% below target of 1000 annual EEDs every six months to 60% over target after implementation of an autonomous AI.
Case Study
LumineticsCore Improves Rates of Annual Eye Exams for Diabetes and Reduces Time-to-Follow-Up in a Complex Population at Tarzana Treatment Centers
There was a significant difference between the proportion of patients with diabetes completing their annual eye exam for diabetes with LumineticsCore compared to remote reading networks and there was a reduction in time-to-follow up from 60 days with a remote reading network to 5 days with LumineticsCore
Case Study
AbsoluteCare Healthcare System Implements Autonomous AI Diagnostic Testing to Streamline Care During Wellness Checks and Preserve Vision for People Living with Diabetes
LumineticsCore allowed AbsoluteCare’s providers to effectively determine if a patient was negative for DR, or if they should immediately seek the care of an eyecare specialist to treat the developing DR and halt its progression.
Publication
Study Finds Autonomous AI Boosts Medical Caregivers’ Productivity by 40% in Bangladesh
Autonomous AI increases healthcare system productivity, which could potentially increase access and reduce health disparities. The first randomized trial ever to be published on the efficiency gains of autonomous AI.
Publication
Scaling Adoption of Medical AI — Reimbursement from Value-Based Care and Fee-for-Service Perspectives
“Sustainable reimbursement will be key to scaling adoption — and thereby, realizing the potential benefits of medical AI to better health outcomes for all.”
Publication
Considerations for addressing bias in artificial intelligence for health equity
By focusing on the goal of ensuring health equity along the total product life cycle (TPLC) framework, stakeholders can collectively identify and mitigate inequities, leading to better health outcomes for all.
Publication
Real world outcomes from artificial intelligence to detect diabetic retinopathy in a primary care setting: 12-month experience
LumineticsCore Facilitates Care Gap Closure at Stanford Health System with Documented Achievement Surpassing 90th Percentile of HEDIS
Read More- 30.3% of those referred after an AI-based exam followed up at the university eye institute compared with 11.5% of people referred for follow up after teleophthalmology testing.
- The percentage of patients that received an annual eye exam increased from 65.2% to 72.8% in the clinics utilizing IDx-DR, exceeding the 90th percentile national benchmark (67.89%) for the Healthcare Effectiveness Data and Information Set (HEDIS) quality measure.
Digital Diagnostics
Research
Digital Diagnostics is actively looking into additional ways to leverage fundus imaging for AI based diagnostic solutions.
Exploring Glaucoma
Glaucoma is a group of eye diseases that can cause vision loss and is the second leading cause of blindness in the world.
More information about glaucoma detection coming soon.
Exploring Cardiovascular Indications
Irregularities in the blood vessels of the retina can indicate the extent of injury on blood vessels by hypertension and heart attacks.
More information about potential cardiovascular indications coming soon.
Exploring AMD
Age-related macular degeneration (AMD) is an eye disease that can blur your central vision.
More information about AMD diagnosis coming soon.
Exploring Neurodegenerative Indications
Studies have shown that neurodegenerative changes in the brain are present in the retina.
More information about potential neurodegenerative indications coming soon.
Newsroom
Get the Latest News
About
Explore More
-
About Digital Diagnostics
About Digital Diagnostics
Find out how Digital Diagnostics pioneers AI-driven healthcare, enhancing accessibility, affordability, and quality.
-
History of Digital Diagnostics
History of Digital Diagnostics
Discover how Digital Diagnostics became the first company to receive FDA clearance to diagnose with an AI diagnostic platform without physician input.
-
Founder Story
Founder Story
Learn how Dr. Michael Abramoff envisioned and brought to life the use of computers to help diagnose patients at an earlier stage, enabling effective treatment.
-
Leadership
Leadership
View our Leadership Team, Advisors, and Board of Directors that drive the mission and vision of Digital Diagnostics.
-
Diversity, Equity & Inclusion
Diversity, Equity & Inclusion
Explore Digital Diagnostics' dedication to Diversity, Equity, and Inclusion, shaping the future with ethical AI while making healthcare solutions safe, equitable, and accessible.
About Digital Diagnostics
Find out how Digital Diagnostics pioneers AI-driven healthcare, enhancing accessibility, affordability, and quality.
History of Digital Diagnostics
Discover how Digital Diagnostics became the first company to receive FDA clearance to diagnose with an AI diagnostic platform without physician input.
Founder Story
Learn how Dr. Michael Abramoff envisioned and brought to life the use of computers to help diagnose patients at an earlier stage, enabling effective treatment.
Leadership
View our Leadership Team, Advisors, and Board of Directors that drive the mission and vision of Digital Diagnostics.
Diversity, Equity & Inclusion
Explore Digital Diagnostics' dedication to Diversity, Equity, and Inclusion, shaping the future with ethical AI while making healthcare solutions safe, equitable, and accessible.
Our Mission & Vision Explained
Digital Diagnostics is committed to revolutionizing healthcare worldwide, while prioritizing equitable patient outcomes.
Our Mission
To transform the affordability, accessibility and quality of healthcare worldwide through the automation of medical diagnosis and treatment.
Our Vision
To be the world leader in developing safe, effective, and equitable AI platforms that improve patient outcomes.